We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Accuray (ARAY) Reports Loss in Q4, Revenues Miss Estimates
Read MoreHide Full Article
Accuray Incorporated (ARAY - Free Report) reported fourth-quarter fiscal 2020 loss per share of a penny against the Zacks Consensus Estimate of earnings per share (EPS) of 2 cents. Also, the company had reported a loss of 2 cents per share a year ago.
For fiscal 2020, the company reported EPS of 3 cents against the Zacks Consensus Estimate of a loss of 9 cents. The company had reported a loss of 19 cents per share a year ago.
Revenue Details
For the fiscal fourth quarter, net revenues totaled $95 million, missing the Zacks Consensus Estimate of $99 million by 4%. On a year-over-year basis, revenues fell 19.1%.
For the fiscal year, net revenues came in at $382.9 million, missing Zacks Consensus Estimate by 1.2%. On a year-over-year basis, revenues fell 8.6%.
Fiscal Q4 Details
Product Revenues: Product revenues fell 33.3% year over year to $40.4 million in the reported quarter.
Service Revenues: Service revenues totaled $54.6 million, down 3.9% from the year-ago quarter.
Gross Order Update: Gross orders in the fiscal fourth quarter totaled $94.3 million, down 2.9% year over year.
Margins
Gross profit in the fiscal fourth quarter totaled $39.9 million, down 13.1% on a year-over-year basis.Gross margin was 42%, highlighting an expansion of 289 basis points (bps) year over year.
Fourth-quarter operating profit was $4.6 million, up 39.8%.Operating margin came in at 4.8%, highlighting an expansion of 202 bps.
Accuray Incorporated Price, Consensus and EPS Surprise
The company exited fourth-quarter fiscal 2020 with total cash, cash equivalents, and short-term restricted cash of $108.6 million, compared with $91.6 million at the end of the fiscal third quarter.
2021 Guidance
Considering the continued progression of the COVID-19 pandemic and the uncertainty of its impact on the global economy and the healthcare industry, Accuray has decided not to issue the financial guidance for 2021 with respect to revenues and adjusted EBITDA.
Our Take
Accuray exited the fiscal fourth quarter on a weak note. The company registered decline in both Product and Service revenues in the quarter. We are also concerned about the gross order decline in the quarter. On the bright side, solid demand for the Radixact, CyberKnife and TomoTherapy platforms continues to drive the top line. Expansion of both margins is encouraging as well. In the quarter, the company shipped nine Synchrony upgrades.
Zacks Rank and Key Picks
Accuray currently carries a Zacks Rank #3 (Hold).
A few better-ranked stocks in the broader medical space are Thermo Fisher Scientific Inc. (TMO - Free Report) , PerkinElmer, Inc. and OPKO Health, Inc. (OPK - Free Report) . While OPKO Health carries a Zacks Rank #2 (Buy), the other two sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Thermo Fisher reported second-quarter 2020 adjusted EPS of $3.89, beating the Zacks Consensus Estimate by 45.7%. Revenues of $6.92 billion outpaced the consensus mark by 0.1%.
PerkinElmer reported second-quarter 2020 adjusted EPS of $1.57, surpassing the Zacks Consensus Estimate by 68.8%. Revenues of $811.7 million outpaced the consensus mark by 1.3%.
OPKO Health reported second-quarter 2020 EPS of 5 cents against the Zacks Consensus Estimate of a loss of 7 cents per share. Revenues of $301.2 million surpassed the consensus estimate by 28.4%.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through Q2 2020, while the S&P 500 gained an impressive +44.0%, five of our strategies returned +50.9%, +93.8%, +122.2%, +153.0%, and even +156.8%.
This outperformance has not just been a recent phenomenon. From 2000 – Q2 2020, while the S&P averaged +5.5% per year, our top strategies averaged up to +51.7% per year.
Image: Bigstock
Accuray (ARAY) Reports Loss in Q4, Revenues Miss Estimates
Accuray Incorporated (ARAY - Free Report) reported fourth-quarter fiscal 2020 loss per share of a penny against the Zacks Consensus Estimate of earnings per share (EPS) of 2 cents. Also, the company had reported a loss of 2 cents per share a year ago.
For fiscal 2020, the company reported EPS of 3 cents against the Zacks Consensus Estimate of a loss of 9 cents. The company had reported a loss of 19 cents per share a year ago.
Revenue Details
For the fiscal fourth quarter, net revenues totaled $95 million, missing the Zacks Consensus Estimate of $99 million by 4%. On a year-over-year basis, revenues fell 19.1%.
For the fiscal year, net revenues came in at $382.9 million, missing Zacks Consensus Estimate by 1.2%. On a year-over-year basis, revenues fell 8.6%.
Fiscal Q4 Details
Product Revenues: Product revenues fell 33.3% year over year to $40.4 million in the reported quarter.
Service Revenues: Service revenues totaled $54.6 million, down 3.9% from the year-ago quarter.
Gross Order Update: Gross orders in the fiscal fourth quarter totaled $94.3 million, down 2.9% year over year.
Margins
Gross profit in the fiscal fourth quarter totaled $39.9 million, down 13.1% on a year-over-year basis.Gross margin was 42%, highlighting an expansion of 289 basis points (bps) year over year.
Fourth-quarter operating profit was $4.6 million, up 39.8%.Operating margin came in at 4.8%, highlighting an expansion of 202 bps.
Accuray Incorporated Price, Consensus and EPS Surprise
Accuray Incorporated price-consensus-eps-surprise-chart | Accuray Incorporated Quote
Cash Position
The company exited fourth-quarter fiscal 2020 with total cash, cash equivalents, and short-term restricted cash of $108.6 million, compared with $91.6 million at the end of the fiscal third quarter.
2021 Guidance
Considering the continued progression of the COVID-19 pandemic and the uncertainty of its impact on the global economy and the healthcare industry, Accuray has decided not to issue the financial guidance for 2021 with respect to revenues and adjusted EBITDA.
Our Take
Accuray exited the fiscal fourth quarter on a weak note. The company registered decline in both Product and Service revenues in the quarter. We are also concerned about the gross order decline in the quarter. On the bright side, solid demand for the Radixact, CyberKnife and TomoTherapy platforms continues to drive the top line. Expansion of both margins is encouraging as well. In the quarter, the company shipped nine Synchrony upgrades.
Zacks Rank and Key Picks
Accuray currently carries a Zacks Rank #3 (Hold).
A few better-ranked stocks in the broader medical space are Thermo Fisher Scientific Inc. (TMO - Free Report) , PerkinElmer, Inc. and OPKO Health, Inc. (OPK - Free Report) . While OPKO Health carries a Zacks Rank #2 (Buy), the other two sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Thermo Fisher reported second-quarter 2020 adjusted EPS of $3.89, beating the Zacks Consensus Estimate by 45.7%. Revenues of $6.92 billion outpaced the consensus mark by 0.1%.
PerkinElmer reported second-quarter 2020 adjusted EPS of $1.57, surpassing the Zacks Consensus Estimate by 68.8%. Revenues of $811.7 million outpaced the consensus mark by 1.3%.
OPKO Health reported second-quarter 2020 EPS of 5 cents against the Zacks Consensus Estimate of a loss of 7 cents per share. Revenues of $301.2 million surpassed the consensus estimate by 28.4%.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through Q2 2020, while the S&P 500 gained an impressive +44.0%, five of our strategies returned +50.9%, +93.8%, +122.2%, +153.0%, and even +156.8%.
This outperformance has not just been a recent phenomenon. From 2000 – Q2 2020, while the S&P averaged +5.5% per year, our top strategies averaged up to +51.7% per year.
See their latest picks free >>